Processa Pharmaceuticals, Inc. Announces Acquisition Of Vidya Therapeutics, Inc. And Approximately $200 Million Concurrent Private Placement To Advance Btk Inhibitor, Vt-7208, In Multiple Disease Areas
PCSA•Processa announces acquisition and private placement
July 29 (Reuters) - Processa Pharmaceuticals Inc (PCSA.O):
- Processa Pharmaceuticals, Inc. announces acquisition of Vidya Therapeutics, Inc. and approximately $200 million concurrent private placement to advance Btk inhibitor, VT-7208, in multiple disease areas
Related News
SciSparc subsidiary NeuroThera Labs validates quantum sampling workflow for clinical trials analytics platform
SPRC•
Icecure Sio Petitions NCCN To Include Cryoablation In Breast Cancer Treatment Guidelines, Citing Icecure's FDA Clearance Of Prosense®
ICCM•
